Elite Diagnostic Limited (JMSE:ELITE)
Jamaica · Delayed Price · Currency is JMD 1.790
-0.010 (-0.56%)
At close: Oct 16, 2026
Elite Diagnostic Income Statement
Financials in millions JMD. Fiscal year is July - June.
Millions JMD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 867.29 | 853.82 | 821.28 | 755.33 | 624.22 | |
Revenue Growth | 1.58% | 3.96% | 8.73% | 21.00% | 23.14% |
Cost of Revenue | 248.2 | 269.69 | 278.13 | 277.27 | 223.58 |
Gross Profit | 619.09 | 584.14 | 543.16 | 478.06 | 400.64 |
Selling, General & Admin | 362.63 | 342.65 | 311.39 | 276.9 | 210.66 |
Operating Expenses | 542.01 | 512.76 | 446.61 | 413.35 | 318.19 |
Operating Income | 77.08 | 71.38 | 96.54 | 64.71 | 82.45 |
Interest Expense | -48.31 | -28.24 | -48.64 | -32.67 | -27.33 |
Interest & Investment Income | 1.29 | 0.13 | 0.09 | 0.1 | 0.01 |
Currency Exchange Gain (Loss) | 2.67 | 2.62 | -3.32 | -4.56 | -6.47 |
Other Non Operating Income (Expenses) | - | -10.9 | -14.15 | -14.2 | - |
EBT Excluding Unusual Items | 32.72 | 34.99 | 30.53 | 13.39 | 48.66 |
Asset Writedown | -0.82 | 1.93 | -1.18 | - | - |
Pretax Income | 31.91 | 36.92 | 29.35 | 13.39 | 48.66 |
Income Tax Expense | 4.31 | 4.9 | 3.19 | 0.04 | - |
Net Income | 27.6 | 32.02 | 26.16 | 13.35 | 48.66 |
Net Income to Common | 27.6 | 32.02 | 26.16 | 13.35 | 48.66 |
Net Income Growth | -13.82% | 22.44% | 95.90% | -72.56% | 2422.31% |
Shares Outstanding (Basic) | 353 | 353 | 353 | 353 | 353 |
Shares Outstanding (Diluted) | 353 | 353 | 353 | 353 | 353 |
Shares Change | - | - | - | - | - |
EPS (Basic) | 0.08 | 0.09 | 0.07 | 0.04 | 0.14 |
EPS (Diluted) | 0.08 | 0.09 | 0.07 | 0.04 | 0.14 |
EPS Growth | -13.82% | 22.44% | 95.91% | -72.56% | 2422.72% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -291.86 | 167.95 | 92.29 | -25.87 | -127.87 |
Free Cash Flow Per Share | -0.83 | 0.47 | 0.26 | -0.07 | -0.36 |
Dividend Per Share | - | 0.010 | - | - | 0.020 |
Dividend Growth | - | - | - | - | -77.78% |
Gross Margin | 71.38% | 68.41% | 66.14% | 63.29% | 64.18% |
Operating Margin | 8.89% | 8.36% | 11.76% | 8.57% | 13.21% |
Profit Margin | 3.18% | 3.75% | 3.19% | 1.77% | 7.80% |
Free Cash Flow Margin | -33.65% | 19.67% | 11.24% | -3.43% | -20.48% |
EBITDA | 218.56 | 206.47 | 199.83 | 173.05 | 177.25 |
EBITDA Margin | 25.20% | 24.18% | 24.33% | 22.91% | 28.40% |
D&A For EBITDA | 141.48 | 135.1 | 103.29 | 108.33 | 94.8 |
EBIT | 77.08 | 71.38 | 96.54 | 64.71 | 82.45 |
EBIT Margin | 8.89% | 8.36% | 11.76% | 8.57% | 13.21% |
Effective Tax Rate | 13.50% | 13.27% | 10.88% | 0.26% | - |
Advertising Expenses | 1.4 | 3.42 | 5.23 | 9.61 | 5.9 |